Navigation Links
Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Date:11/14/2011

MENLO PARK, Calif., Nov. 14, 2011 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cysteine protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer, presented data showing that one of the company's spectrum-selective cathepsin inhibitors demonstrated efficacy in a mouse model of bone cancer pain.  Virobay has a series of advanced, spectrum-selective cathepsin inhibitors with structural diversity and demonstrated activity in bone cancer and related pain.  VBY-825, a prototype compound within this series, is an orally bioavailable, highly potent, reversible inhibitor of a subset of cathepsin proteases (including cathepsins S, K, L and B) that demonstrated protection from bone destruction and remodeling in this metastatic breast cancer model, as well as significant analgesic activity.  These preclinical data suggest that Virobay's spectrum-selective cathepsin inhibitors have potential therapeutic utility in the treatment of metastatic and primary bone cancer and cancer-related bone pain, with a mechanism of action that would be highly complementary to standard chemotherapy.

The data were presented in a poster, titled "Efficacy of a Spectrum-Selective Cathepsin Inhibitor in a Mouse Model of Bone Cancer," by Holsinger, et al., at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, on Sunday, November 13th.

"These preclinical data provide a compelling demonstration of the therapeutic potential of Virobay's cathepsin inhibitors in bone cancer and bone cancer pain," said Robert Booth, PhD, Virobay's president and chief executive officer.  "The data demonstrate that the anti-tumorigenic and analgesic activity is due to the selective targeting of specific cathepsins that are known to facilitate osteolytic metastasis, bone invasion and bone matrix degradation.  We believe that these dat
'/>"/>

SOURCE Virobay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Study Shows C1-Esterase Inhibitor Concentrate is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. Enantas Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhovers Top 10 Infectious Disease Projects to Watch
6. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
7. Modulation of inhibitory output is key function of antiobesity hormone
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
10. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
11. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  Synthetic Biologics, ... serious infections and diseases, with a focus on protecting the ... Officer, is scheduled to present at the 27th Annual ROTH ... Laguna Niguel in Dana ... on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time). ...
(Date:3/3/2015)... PHILADELPHIA , March 2, 2015  Phillip Sharp, ... faculty member of the Department of Biology and the Koch ... Gold Medal at Heritage Day , May 14, ... recipient of the Othmer Gold Medal since it was ... "In 1977 Phil Sharp gave the ...
(Date:3/2/2015)... 2015 Resilinc released online ... which summarizes and analyzes nearly 700 unique supply ... 24X7 global event monitoring and alert reporting service. ... free trial period of the email service to receive ... can negatively impact revenue, market share, customer satisfaction, and ...
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics, today announced ... Barclays Global Healthcare Conference in Miami, FL at the Loews ... chief executive officer of Pfenex, will provide an ... strategy on March 12th at 9:00 am ET. A live audio ...
Breaking Biology Technology:Synthetic Biologics to Present at the 27th Annual ROTH Conference 2Phillip Sharp to Receive 2015 Othmer Gold Medal 2Phillip Sharp to Receive 2015 Othmer Gold Medal 3Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 2Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 3
... drug,and diagnostic company, today announces that Loic Maurel, ... Chief Operating Officer. At the next,meeting of the ... du,Directoire)., Laurent Condomine, Chairman of the Supervisory ... joining ExonHit Therapeutics. His,experience and track record in ...
... − Every year, one million Europeans are confronted with ... traffic accidents. Because the nerves in a damaged spinal ... remains (partially) paralyzed. Now, VIB scientists connected to the ... simple model that enables the study of injured brain ...
... GE Energy, manufacturer of Reuter Stokes radiation detection equipment, ... electronics and software associated with the SNS 8Pack neutron ... sensitive neutron detectors developed at Oak Ridge National Laboratory. ... detection system that was developed for the Department of ...
Cached Biology Technology:Loic Maurel Joins Exonhit Therapeutics to Become CEO 2Loic Maurel Joins Exonhit Therapeutics to Become CEO 3Loic Maurel Joins Exonhit Therapeutics to Become CEO 4Microsurgery on the brain of the fruit fly leads to new insights into irreparable nerve injuries 2GE Energy to market SNS-developed detector electronics system 2
(Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... which lead poisoning has struck young Rhode Island children depends ... geographic analysis of comprehensive health department data from across Rhode ... poisoning, researchers have been able to help target cleanup resources ... some census blocks in the state had no cases of ...
... predatory crabs due to global warming could threaten the ... findings. "King crabs are ecologically important predators ... said Dr Sven Thatje, an evolutionary ecologist at the ... (SOES), which is based at the National Oceanography Centre ...
... Established in 2007 and based in Toronto, ArcticDx ... its kind and specifically designed to determine one,s inherited ... form of acquired blindness in the developed world, affecting ... PBDF investment to undertake studies in support of a ...
Cached Biology News:Lead poisoning maps in R.I. reveal huge disparities, guide cleanup 2King crab distributions limited by temperature in the Southern Ocean 2OGI invests in personalized medicine for age-related macular degeneration 2
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
...
...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products: